Kymera Therapeutics, Inc. - Common Stock — Bilancio Trimestrale (NASDAQ:KYMR) | MetaTrader

Apri il grafico completo Full chart

Notizie

Kymera presenta i dati del trial KT-621 per la dermatite atopica

Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Kymera presenta dati preclinici per il candidato farmaco IBD KT-579

Kymera Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:KYMR) 2026-05-04

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Kymera Therapeutics: risultati trimestrali dopo l’accordo con Gilead

Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates

KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug

FDA concede status fast track a KT-621 di Kymera per l’asma

KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200

H.C. Wainwright conferma il rating buy su Kymera Therapeutics